Tempest Therapeutics Inc（TPST）股票分析TPSTTempest Therapeutics Inc

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tempest Therapeutics Inc (TPST) is not a good buy right now. The current price is $0.3801, which is significantly lower than the 52-week high of $10.33, indicating a drastic decline of 96.12% over the past year. Additionally, the RSI is at a very low 10.575, suggesting extreme oversold conditions, but this could reflect deeper underlying issues rather than a buying opportunity. The company has reported a net income loss of $27,696,000 for Q1 2026, which raises concerns about its financial stability. The recent financing news has not positively impacted the stock, as it fell 4.60% after announcing a private placement to raise $2.5 million, reflecting market skepticism about its future prospects. The main risk is the company's ongoing losses and reliance on external funding, which could further dilute shareholder value.